Katy Jeannot

4.2k total citations
73 papers, 2.4k citations indexed

About

Katy Jeannot is a scholar working on Molecular Medicine, Molecular Biology and Pharmacology. According to data from OpenAlex, Katy Jeannot has authored 73 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Molecular Medicine, 32 papers in Molecular Biology and 21 papers in Pharmacology. Recurrent topics in Katy Jeannot's work include Antibiotic Resistance in Bacteria (58 papers), Bacterial biofilms and quorum sensing (28 papers) and Antibiotics Pharmacokinetics and Efficacy (19 papers). Katy Jeannot is often cited by papers focused on Antibiotic Resistance in Bacteria (58 papers), Bacterial biofilms and quorum sensing (28 papers) and Antibiotics Pharmacokinetics and Efficacy (19 papers). Katy Jeannot collaborates with scholars based in France, Germany and United States. Katy Jeannot's co-authors include Patrick Plésiat, Arnaud Bolard, Patrick Plésiat, Patrick Plésiat, Cédric Muller, Pierre‐Edouard Fournier, Patrick Plésiat, Isabelle Broutin, Ina Attrée and Didier Hocquet and has published in prestigious journals such as Angewandte Chemie International Edition, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Katy Jeannot

70 papers receiving 2.4k citations

Peers

Countries citing papers authored by Katy Jeannot

Since Specialization

Citations

This map shows the geographic impact of Katy Jeannot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katy Jeannot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katy Jeannot more than expected).

Fields of papers citing papers by Katy Jeannot

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Katy Jeannot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katy Jeannot. The network helps show where Katy Jeannot may publish in the future.

Co-authorship network of co-authors of Katy Jeannot

This figure shows the co-authorship network connecting the top 25 collaborators of Katy Jeannot. A scholar is included among the top collaborators of Katy Jeannot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Katy Jeannot. Katy Jeannot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Contribution of mutational resistance mechanisms and acquired β-lactamases to cefiderocol/xeruborbactam susceptibility in Pseudomonas aeruginosa 2025 ·Antimicrobial Agents and Chemotherapy ·(unknown), María A. Gomis-Font, (unknown), (unknown), Salud Rodríguez-Pallares, (unknown), Alejandro Beceiro, Germán Bou, Katy Jeannot, Antonio Oliver, Jorge Arca-Suárez	0
2	Cefiderocol susceptibility testing: the challenge of disc diffusion 2025 ·Clinical Microbiology and Infection ·Katy Jeannot, Laurent Dortet, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	4
3	Computational Design of Pore-Forming Peptides with Potent Antimicrobial and Anticancer Activities 2024 ·Journal of Medicinal Chemistry ·(unknown), Marcelo D. T. Torres, (unknown), (unknown), Floriana Cappiello, (unknown), (unknown), (unknown), (unknown), Katy Jeannot, Miloš Petřík, Maria Luisa Mangoni, Gabriela Balíková Novotná, Marek Mráz, César de la Fuente‐Núñez, Robert Vácha	9
4	Pseudomonas aeruginosa MipA-MipB envelope proteins act as new sensors of polymyxins 2024 ·mBio ·(unknown), Viviana Job, Maxime Bour, Mylène Robert‐Genthon, Sabine Brugière, (unknown), David Cobessi, Yohann Couté, Katy Jeannot, Ina Attrée	6
5	Performance of the Disc Diffusion Method, MTS Gradient Tests and Two Commercially Available Microdilution Tests for the Determination of Cefiderocol Susceptibility in Acinetobacter spp. 2023 ·Microorganisms ·Katy Jeannot, (unknown), (unknown), (unknown), (unknown), Pierre‐Edouard Fournier, Anaïs Potron	13
6	Phenotypic Characterization and Prevalence of Carbapenemase-Producing Pseudomonas aeruginosa Isolates in Six Health Facilities in Cameroon 2023 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Teke Apalata, Katy Jeannot	10
7	Evaluation of 5 rapid colorimetric and immunochromatographic tests for the detection of carbapenemases in Pseudomonas aeruginosa and Acinetobacter spp. isolates 2023 ·European Journal of Clinical Microbiology & Infectious Diseases ·Pierre‐Edouard Fournier, (unknown), (unknown), Patrick Plésiat, Katy Jeannot, Anaïs Potron	1
8	6-Polyaminosteroid Squalamine Analogues Display Antibacterial Activity against Resistant Pathogens 2023 ·International Journal of Molecular Sciences ·(unknown), (unknown), Florie Desriac, Magalie Barreau, (unknown), (unknown), François Sichel, Katy Jeannot, Jean-Christophe Giárd, David Garon, Sylvie Chevalier, Cécile Muller, Emmanuelle Dé, Jean Michel Brunel	3
9	Evaluation of the Efficiency of Random and Diblock Methacrylate-Based Amphiphilic Cationic Polymers against Major Bacterial Pathogens Associated with Cystic Fibrosis 2023 ·Antibiotics ·Magali Casanova, Hamza Olleik, (unknown), (unknown), Jean‐François Cavalier, Vanessa Point, Katy Jeannot, (unknown), Josette Perrier, (unknown), Mickaël Lafond, Yohann Guillaneuf, Stéphane Canaan, Catherine Lefay, Marc Maresca	7
10	Poly-L-Lysine to Fight Antibiotic Resistances of Pseudomonas aeruginosa 2023 ·International Journal of Molecular Sciences ·(unknown), (unknown), Virginie Vasseur, Katy Jeannot, (unknown), Mustapha Si‐Tahar, Virginie Hervé	5
11	Cefiderocol activity is compromised by acquired extended-spectrum oxacillinases in Pseudomonas aeruginosa 2023 ·International Journal of Antimicrobial Agents ·(unknown), (unknown), Maxime Bour, Céline Landon, Patrick Plésiat, Katy Jeannot	11
12	Number, type and cost of microbiological tests during HIV Pre-Exposure Prophylaxis: The experience of a French hospital 2020 ·Infectious Diseases Now ·(unknown), Kévin Bouiller, (unknown), (unknown), (unknown), Thomas W. LeBlanc, Katy Jeannot, Catherine Chirouze, Laurent Hustache‐Mathieu, Quentin Lepiller	1
13	Azetidine‐Containing Alkaloids Produced by a Quorum‐Sensing Regulated Nonribosomal Peptide Synthetase Pathway in Pseudomonas aeruginosa 2018 ·Angewandte Chemie International Edition ·Zhilai Hong, Arnaud Bolard, Caroline Giraud, Sébastien Prévost, Grégory Genta‐Jouve, Christiane Deregnaucourt, Susanne Häußler, Katy Jeannot, Yanyan Li	38
14	Azetidine‐Containing Alkaloids Produced by a Quorum‐Sensing Regulated Nonribosomal Peptide Synthetase Pathway in Pseudomonas aeruginosa 2018 ·Angewandte Chemie ·Zhilai Hong, Arnaud Bolard, Caroline Giraud, Sébastien Prévost, Grégory Genta‐Jouve, Christiane Deregnaucourt, Susanne Häußler, Katy Jeannot, Yanyan Li	5
15	Mycoplasma genitalium and Trichomonas vaginalis in France: a point prevalence study in people screened for sexually transmitted diseases 2016 ·Clinical Microbiology and Infection ·Sabine Pereyre, (unknown), Cécile Bébéar, (unknown), A. Beby‐Defaux, Béatrice Berçot, Sandrine Boisset, Nadine Bourgeois, (unknown), Dominique Decré, (unknown), Stéphane Gibaud, (unknown), Katy Jeannot, Marie Kempf, France Moreau, J. Petitjean-Lecherbonnier, M.-F. Prère, H. Salord, Paul O. Verhoeven	33
16	Complexity of resistance mechanisms to imipenem in intensive care unit strains of Pseudomonas aeruginosa 2013 ·Journal of Antimicrobial Chemotherapy ·Pierre‐Edouard Fournier, (unknown), (unknown), (unknown), Catherine Llanes, Patrick Plésiat, Katy Jeannot	67
17	Correction: Unique Biofilm Signature, Drug Susceptibility and Decreased Virulence in Drosophila through the Pseudomonas aeruginosa Two-Component System PprAB 2012 ·PLoS Pathogens ·Sophie de Bentzmann, Caroline Giraud, C. Bernard, Virginie Calderon, Friederike Ewald, (unknown), Cathy Nguyen, Didier Grünwald, Ina Attrée, Katy Jeannot, Marie‐Odile Fauvarque, Christophe Bordi	9
18	A Two-Component Regulatory System Interconnects Resistance to Polymyxins, Aminoglycosides, Fluoroquinolones, and β-Lactams in Pseudomonas aeruginosa 2010 ·Antimicrobial Agents and Chemotherapy ·Cédric Muller, Patrick Plésiat, Katy Jeannot	168
19	Pseudomonas aeruginosa May Accumulate Drug Resistance Mechanisms without Losing Its Ability To Cause Bloodstream Infections 2007 ·Antimicrobial Agents and Chemotherapy ·Didier Hocquet, P. Berthelot, Micheline Roussel‐Delvallez, Roger Favre, Katy Jeannot, Odile Bajolet, N. Marty, Florence Grattard, Patricia Mariani‐Kurkdjian, Édouard Bingen, Marie-Odile Husson, G. Couetdic, Patrick Plésiat	82
20	Bacteriostatic and bactericidal activities of eight fluoroquinolones against MexAB-OprM-overproducing clinical strains of Pseudomonas aeruginosa 2005 ·Journal of Antimicrobial Chemotherapy ·(unknown), Didier Hocquet, Katy Jeannot, P. Chavanet, Patrick Plésiat	30

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact